Neoplasm Of Prostate

UMLS: C0033578
Basic Information
Severity Level:
Severe
Definition:
Tumors or cancer of the PROSTATE.
UMLS ID:
C0033578
MeSH ID:
D011471
Synonyms:
Neoplasm Of Prostate
Ngp - New Growth Of Prostate
Neoplasm Of Prostate
Neoplasm Of Prostate
Neoplasm Of The Prostate
Neoplasm Prostate
Prostate Neoplasia
Prostate Tumor
Prostate Neoplasm
Prostate Tumor
Prostate Neoplasm
Prostatic Neoplasms
Tumor Of Prostate
Tumor Of Prostate
Tumor Of The Prostate
Tumour Of Prostate
Neoplasia Prostate
Neoplasm Of Prostate Gland
Neoplasm Of The Prostate
Prostate Neoplasm
Prostate Neoplasms
Prostate Tumor
Classification Hierarchy
MeSH Tree Number breakdown for C0033578
C04
Neoplasms
Category: Neoplasms Parent: C (Diseases) Level: 0
C04.588
Neoplasms by Site
Category: Neoplasms Parent: C04 Level: 1
C04.588.945
Urogenital Neoplasms
Category: Neoplasms Parent: C04.588 Level: 2
C04.588.945.440
Genital Neoplasms, Male
Category: Neoplasms Parent: C04.588.945 Level: 2
C04.588.945.440.770
Prostatic Neoplasms
Category: Neoplasms Parent: C04.588.945.440 Level: 3 Tree Number: C04.588.945.440.770
C12
Urogenital Diseases
Category: Male Urogenital Diseases Parent: C (Diseases) Level: 0 Tree Number: C12
C12
Urogenital Diseases
Category: Male Urogenital Diseases Parent: C (Diseases) Level: 0 Tree Number: C12
C12
Urogenital Diseases
Category: Male Urogenital Diseases Parent: C (Diseases) Level: 0 Tree Number: C12
Similar ADEs in This Classification
Neoplasia Of The Penis
UMLS: C0030849
57%
Ca - Cancer Of Penis
UMLS: C0153601
57%
Neoplasm Of Testis
UMLS: C0039590
40%
Malignant Neoplasm Of Testis
UMLS: C0153594
40%
Prostatic Hyperplasia
UMLS: C0005001
29%
Inflammation Of Prostate
UMLS: C0033581
29%
Adenoma - Prostate
UMLS: C0520477
29%
Bep - Benign Enlargement Of Prostate
UMLS: C1704272
29%
Epididymitis
UMLS: C0014534
28%
Disease Of Penis, Nos
UMLS: C0030846
28%
Spermatic Cord Torsion
UMLS: C0037856
28%
Blood (In);Semen
UMLS: C0149707
28%
ADE Molecular Mechanism Mapping

Drug-ADE-Human Protein Triplets

Molecular mechanism triplets showing drug-adverse event-protein relationships

4997 Total Triplets
313 High Confidence
Loading Drug-ADE-Protein triplets...
Personalized Drug-Protein-ADE Network

Comprehensive Information for Personalized ADE

Comprehensive Information and Reliability for Drug-ADE Association

Drug Confidence Filter
DTA Confidence Level
Layout Style
Show Labels
Total Drugs
316
0 High | 22 Medium | 294 Low Confidence
Total Proteins
595
Target proteins associated with this ADE
Drug-Protein-ADE association
25721
18 Known | 295 High | 4684 Middle | 20724 Low Confidence
Confidence Profile
19%
Known/High/Middle-confidence interactions

This interactive network visualization shows the relationships between the top 50 drugs (ranked by case number) out of 316 total drugs associated with this adverse event, their known and potential off-target proteins, and the associated adverse effect. The connections indicate binding interactions and mechanistic pathways.

Adverse Drug Event (ADE)
Drug
Protein
Drug-Center
Human Protein-Center
confidence level

Drug Confidence Level Distribution

Drug Type Distribution

Loading ADE information...

Pharmacological Target Class Distribution

Top 8 Function Target Sub Classes

Loading target information...
The Introduction of Drug-AE Confidence Score Grade
Priority Level Score Range Description Evidence Characteristics
High Score ≥ 6.67
High-priority associations requiring immediate attention. 		Strong evidence across multiple dimensions with high statistical significance, robust association measures, and substantial case numbers. Warrant priority pharmacovigilance action. High P-value scores (significant Adjust-P), Strong ROR/PRR values, Substantial case numbers, Complete dimensional coverage, Minimal data filtering needed.
Medium 3.33 ≤ Score < 6.67
Medium-priority associations requiring careful evaluation.		 Moderate evidence quality with acceptable statistical significance and association strength. May need additional validation or monitoring before definitive action. Moderate P-value significance, Reasonable ROR/PRR measures, Adequate case numbers, Partial dimensional coverage, Some data quality considerations.
Low Score < 3.33
Low-priority associations with limited evidence strength. 		May represent weak signals, insufficient data, or associations requiring extensive additional investigation before any regulatory or clinical consideration. Weak P-value significance, Low association measures, Limited case numbers, Incomplete dimensional data, Significant data filtering applied.
PersDTA overview
The Introduction of Drug-AE Severity Score Grade
Severity Level Score Range Description Typical outcomes
Minimal 0 ≤ Score ≤ 0.387
Low severity ADRs requiring minimal intervention.		 Events that need medical attention to prevent permanent damage but without hospitalization or life-threatening consequences. Primarily RI (Required Intervention) outcomes, Outpatient management, Preventive measures, Early intervention prevents escalation.
Mild 0.387 < Score ≤ 0.861
Mild severity events requiring hospitalization.		 Mix of intervention-required and hospitalization cases with manageable clinical outcomes and good recovery potential. Mix of RI and HO outcomes, Initial or prolonged hospitalization, Active medical management, Generally favorable prognosis.
Moderate 0.861 < Score ≤ 1.500
Moderate ADRs resulting in permanent disability.		 Higher proportion of hospitalization and disability cases requiring intensive medical management and long-term care planning. Increased HO and DS outcomes, Permanent disability, Extended hospitalization, Rehabilitation required, Long-term functional impairment.
Severe 1.500 < Score ≤ 2.52
High severity life-threatening events with significant morbidity.		 Notable presence of disability and life-threatening outcomes requiring emergency intervention and intensive care management. Prominent DS and LT outcomes, Life-threatening events, Emergency intervention required, ICU admission, High risk of permanent consequences.
Critical 2.524 < Score ≤ 5.000
Critical life-threatening or fatal ADRs with maximum clinical impact.		 High proportion of life-threatening events and deaths with very strong drug-event associations requiring immediate regulatory action. Significant LT and DE outcomes, Fatal events, Emergency life-support measures, Immediate drug discontinuation, Regulatory safety alerts.
The Introduction of Drug-AE-Protein Confidence Score Grade
Confidence Level Relationships Description Evidence Types
Known/Valid Direct DTA relationships The drug-ADE, drug-target, and target-ADE associations are all derived from the same literature source. Experimental validation, Clinical evidence
High DT + TA + DA Two of the three associations (drug-ADE, drug-target, and target-ADE) are derived from the same literature source, while the third is validated by other literature. Multiple corroborating sources
Medium DT + TA + DA Two of the three associations (drug-ADE, drug-target, and target-ADE) are validated by separate literature sources. Partial evidence chain
Low TA + DT Only target-ADE and drug-target associations are validated by literature sources. Associative evidence only
Personalized ADE

Route and Formulation-specified Associations

Pharmaceutic Granularity for Route and Formulation specification

Administration Routes (Total: 171 cases across 8 routes)

Dosage Forms (Total: 74 cases across 9 forms)

Drug Route Analysis
Drug Form Analysis

Drug Route Analysis

Route Drug Name Case Number Confidence Score Confidence Level Severity Score Severity Level Details
Loading data...

Drug Form Analysis

Form Drug Name Case Number Confidence Score Confidence Level Severity Score Severity Level Details
Loading data...

Disease-stratified Associations

Personalized Granularity for Disease and Indication Stratification

Indication Name
Drug Name
Case Number
Confidence Score
Confidence Level
Severity Score
Severity Level
Details